Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Potentially Transformative Long-Acting Therapeutic for Drug-Resistant Tuberculosis
Favorable safety and tolerability across all dose levels; pharmacokinetics support the potential for infrequent dosing; multiple-ascending-dose study now underway KIGALI, Rwanda, July 20, 2026 /PRNewswire/ -- Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing...
Favorable safety and tolerability across all dose levels; pharmacokinetics support the potential for infrequent dosing; multiple-ascending-dose study now underway KIGALI, Rwanda, July 20, 2026 /PRNewswire/ -- Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.